Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 17/20 | 0.47 |
| ▸ | CA1 | P00915 | 13/20 | 0.47 |
| ▸ | CA12 | O43570 | 12/20 | 0.47 |
| ▸ | CA9 | Q16790 | 13/20 | 0.44 |
| ▸ | CA5A | P35218 | 6/20 | 0.44 |
| ▸ | CA7 | P43166 | 6/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.44 |
| ▸ | CA6 | P23280 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22013599 | 0.86 | KAT2B (0.36) | ALDH1A1CA2CA1CA12CA9 | |
| SCHEMBL25034010 | 0.82 | ALDH1A1 (0.38) | ALDH1A1CA2CA1CA12CA9 | |
| SCHEMBL22013598 | 0.76 | KAT2B (0.31) | — | |
| SCHEMBL20680962 | 0.76 | ALDH1A1 (0.56) | ALDH1A1CA2CA1CA12CA9 | |
| SCHEMBL30003292 | 0.74 | CA2 (0.54) | ALDH1A1CA2CA1CA12CA9 | |
| SCHEMBL21962531 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CA2CA1CA12CA9 | |
| SCHEMBL25034032 | 0.71 | L3MBTL1 (0.36) | ALDH1A1CA2CA1LMNAPOLB | |
| SCHEMBL8428532 | 0.71 | ALDH1A1 (0.60) | ALDH1A1CA2CA1CA12CA9 | |
| SCHEMBL21962202 | 0.71 | PYCR1 (0.42) | ALDH1A1LMNA | |
| SCHEMBL22013603 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 1999/4885CA2 1210/4885CA1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.